Non-Invasive Prenatal Testing (NIPT) Market Overview and Introduction

Non-Invasive Prenatal Testing (NIPT) is a method to determine risks associated with certain genetic abnormalities in fetuses. Noninvasive prenatal testing (NIPT), also referred to as Non-Invasive Prenatal Screening (NIPS), involves analysis of small fragments of DNA that are circulating in a pregnant woman’s blood. These fragments of DNA, called cell-free DNA (cfDNA), are obtained from the placenta and provide an opportunities for early detection of certain genetic abnormalities. The test is preferred owing to its noninvasive nature, which involves collecting a blood sample only from pregnant women without posing any risks to the fetus. NIPT is primarily performed for the identification of chromosomal disorders such as Down syndrome (also called trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome. In addition, it can also screen additional chromosomal disorders, which are caused due to missing (deleted) or copied (duplicated) sections of a chromosome.

The global Non-Invasive Prenatal Testing (NIPT) market is majorly driven by growing risks of chromosomal disorders in fetuses with an increase in maternal age. Moreover, increasing developmental strategies by key players, such as agreements, partnerships, collaborations, and expansions, are contributing significantly to market growth. However, complex methodologies employed in noninvasive prenatal tests pose challenges for healthcare providers, which are likely to restrain market growth to a certain extent.

The global Non-Invasive Prenatal Testing (NIPT)  market is segmented into product, method, application, end-user, and region.

Non-Invasive Prenatal Testing (NIPT) Market by Product

On basis of product, the non-invasive prenatal testing market can be segmented into consumables, instruments, and services. The services segment is estimated to grow at a robust CAGR. The fastest growth of this segment is attributed to increasing government initiatives to provide prenatal testing services that help to identify genetic abnormalities at fetal stages.

Non-Invasive Prenatal Testing (NIPT) Market by Method

Based on method, the market can be segmented into biochemical screening tests, ultrasound detection, cell-free DNA in maternal plasma tests, and fetal cells in maternal blood tests. The cell-free DNA in the maternal plasma tests segment is estimated to grow at a robust CAGR. The increasing number of products based on the application of cell-free DNA for NIPT are contributing to the growth of this segment.

Non-Invasive Prenatal Testing (NIPT) Market by Application

Similarly, in terms of application, the non-invasive prenatal testing market can be segmented into trisomy, microdeletion syndrome, and others. The trisomy segment is estimated to grow at the highest rate during the forecast period owing to the high prevalence of trisomy-related genetic disorders such as Down syndrome, Edward syndrome, and Patau syndrome.

Non-Invasive Prenatal Testing (NIPT) Market by End User

Based on end-user, the market can be segmented into diagnostic laboratories and hospitals. The increasing implementation of non-invasive prenatal testing in diagnostic laboratories is promoting the growth of this segment.

Non-Invasive Prenatal Testing (NIPT) Market by Region

The global non-invasive prenatal testing market can be segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the non-invasive prenatal testing market followed by Europe and Asia Pacific. The advanced healthcare infrastructure, better government policies for the promotion of non-invasive testing methods, and presence of key players can be attributed to the market growth in North America.  

Non-Invasive Prenatal Testing Market (NIPT) Prominent Players

Some of the prominent players in the non-invasive prenatal testing market include Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, QIAGEN, BGI, Agilent Technologies, Inc., Natera, Inc., YOURGENE HEALTH, CENTOGENE N.V., and PerkinElmer Inc., among others.